Ftse Mib
33.707,21
-0,38%
DAX
18.177,62
-0,90%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.790,82
-0,02%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Immutep Ltd (IMMP) Immutep Ltd (IMMP) Notizie

Immutep Ltd

IMMP
2,63
-0,03 (-1,13%)
26 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/6/202414:00GLOBEImmutep Signs Exclusive License Agreement with Cardiff..
05/6/202412:00GLOBEImmutep successfully completes institutional placement and..
04/6/202413:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/6/202402:38GLOBEImmutep Announces Clinical Collaboration with MSD to..
15/5/202414:00GLOBEImmutep Presents Data from Safety Lead-in Phase of AIPAC-003..
02/5/202414:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
29/4/202414:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/4/202414:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/4/202414:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/4/202414:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/3/202414:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
30/1/202422:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/1/202414:00GLOBEImmutep Quarterly Activities Report Q2 FY24
04/1/202414:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
21/12/202314:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
21/12/202312:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/12/202314:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
22/11/202314:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
09/11/202314:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
06/11/202314:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
03/11/202317:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
03/11/202311:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202313:00GLOBEImmutep to Participate in November Investor Events
31/10/202313:00GLOBEImmutep Quarterly Activities Report Q1 FY24
25/10/202314:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
25/10/202312:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
24/10/202314:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
24/10/202312:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
23/10/202314:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
16/10/202314:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
03/10/202314:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
21/9/202314:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
05/9/202315:00GLOBEImmutep to Participate in September Investor Conferences
01/8/202314:00GLOBEImmutep Receives Positive Scientific Advice from European..
31/7/202314:00GLOBEImmutep to Present Overall Survival Data in 1st Line..
28/7/202314:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
28/7/202312:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/6/202314:00GLOBEImmutep Secures Third United States Patent for Eftilagimod..
Apertura: 2,70 Min: 2,60 Max: 2,72
Chiusura: 2,66

La tua Cronologia

NASDAQ
IMMP
Immutep
TG
30L3
Solutions 30
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network